Armata Pharmaceuticals (ARMP) Company Report

Armata Pharmaceuticals, Inc. (ARMP) extended the maturity date to June 1, 2027 for four existing credit agreements with Innoviva Strategic Opportunities LLC, effective January 23, 2026.
The company also extended the expiration date of four outstanding warrant certificates held by Innoviva Strategic Opportunities LLC to January 26, 2031, effective January 23, 2026.
An amendment to the Second Amended and Restated Voting Agreement, effective January 23, 2026, modified its expiration date to the earlier of January 26, 2031, or approval by the U.S. Food and Drug Administration of any of the company's product candidates for marketing and commercial distribution.

Jan 26, 2026, 1:00 PM

8-K

Armata Pharmaceuticals Announces FDA Agreement for AP-SA02 Phase 3 Study

ARMP

New Projects/Investments

Armata Pharmaceuticals (ARMP) announced the conclusion of an End-of-Phase 2 meeting with the FDA, with the agency agreeing to advance its AP-SA02 product candidate into a Phase 3 clinical study for complicated Staphylococcus aureus bacteremia.
This milestone makes Armata the first bacteriophage company to advance a clinical candidate to Phase 3.
The Phase 3 study is anticipated to initiate in the second half of 2026 and will evaluate AP-SA02's superiority over the current standard of care.
The Phase 1b/2a clinical development of AP-SA02 was partially supported by a $26.2 million Department of Defense award.

Jan 13, 2026, 12:10 PM

8-K

Armata Pharmaceuticals to Advance AP-SA02 to Phase 3 Study

ARMP

New Projects/Investments

Armata Pharmaceuticals announced the conclusion of an End-of-Phase 2 (EOP2) written response from the FDA, which agreed that data from the Phase 2a diSArm study supports advancing AP-SA02 to a Phase 3 clinical study for complicated S. aureus bacteremia.
The company plans to initiate the Phase 3 study in the second half of 2026, marking Armata as the first bacteriophage company to advance a clinical candidate to Phase 3.
The FDA provided critical guidance on the Phase 3 study design and is amenable to Armata submitting a request for Qualified Infectious Disease Product Designation (QIDP) for AP-SA02, which the company has already submitted.
The Phase 1b/2a clinical development of AP-SA02 was partially supported by a $26.2 million Department of Defense (DoD) award.

Jan 13, 2026, 12:00 PM

Press Release

Armata Pharmaceuticals Enters At-The-Market Offering Agreement

ARMP

Armata Pharmaceuticals, Inc. entered into a Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC on December 1, 2025.
This agreement establishes an at-the-market offering program allowing the Company to offer and sell shares of its common stock with an aggregate offering price of up to $100,000,000.
JonesTrading Institutional Services LLC will act as the sales agent and will receive a commission of up to 3.0% of the gross sales proceeds of any shares sold.
The Company is not obligated to sell, and JonesTrading is not obligated to buy or sell, any Placement Shares under the agreement.

Dec 1, 2025, 10:17 PM

8-K

Armata Pharmaceuticals Announces KOL Webinar on S. aureus Bacteremia and AP-SA02

ARMP

New Projects/Investments

Armata Pharmaceuticals (ARMP) announced a Key Opinion Leader (KOL) webinar on November 25th, 2025, at 10:00 am EST, to discuss its phage therapy, AP-SA02, for Staphylococcus aureus bacteremia (SAB).
The webinar, hosted by Jones Research, will feature Dr. Vance G. Fowler, Jr., MD, from Duke University School of Medicine, who will discuss the SAB landscape and AP-SA02's potential.
The company highlighted positive results from its diSArm study of AP-SA02 at IDWeek 2025 in October.
The Phase 1b/2a diSArm study showed that AP-SA02 combined with best available antibiotic therapy (BAT) achieved a higher and earlier cure rate and a 100% response rate without relapse at key timepoints, compared to BAT alone, which had an approximate 25% lack of response or relapse.

Nov 18, 2025, 12:00 PM

Press Release

Armata Pharmaceuticals Announces Third Quarter 2025 Results and Corporate Update

ARMP

Earnings

New Projects/Investments

Debt Issuance

Armata Pharmaceuticals reported a net loss of $(26.7 million) for the third quarter ended September 30, 2025, compared to $(5.5 million) for the comparable period in 2024.
The company highlighted positive results from its Phase 2a "diSArm" study of AP-SA02, demonstrating higher and earlier cure rates for complicated Staphylococcus aureus bacteremia compared to placebo.
Armata's state-of-the-art cGMP manufacturing facility in Los Angeles, California, has been formally commissioned.
A $15.0 million secured credit agreement was entered into with Innoviva Strategic Opportunities LLC to advance the development of AP-SA02.
As of September 30, 2025, the company held approximately $14.8 million in unrestricted cash and cash equivalents.

Nov 12, 2025, 9:10 PM

8-K

Armata Pharmaceuticals Announces Third Quarter 2025 Results and Positive Clinical Trial Data

ARMP

Earnings

New Projects/Investments

Armata Pharmaceuticals announced its third quarter 2025 financial results, reporting grant and award revenue of $1.159 million and a net loss of $26.675 million for the period ended September 30, 2025.
The company highlighted positive results from its Phase 2a "diSArm" study of AP-SA02, showing higher and earlier cure rates for complicated Staphylococcus aureus bacteremia.
Armata's state-of-the-art cGMP manufacturing facility in Los Angeles, California, has been formally commissioned, and the company secured a $15.0 million loan to advance AP-SA02 development.
As of September 30, 2025, Armata held approximately $14.8 million in unrestricted cash and cash equivalents.

Nov 12, 2025, 9:05 PM

Press Release

Armata Pharmaceuticals Commissions New cGMP Manufacturing Facility

ARMP

New Projects/Investments

Armata Pharmaceuticals, Inc. has formally commissioned its state-of-the-art current Good Manufacturing Practice (cGMP) manufacturing facility in Los Angeles, California, with production having commenced and full production runs completed without issues.
The 56,000 square foot facility, which includes 10,000 square feet of cGMP clean rooms, will enable Armata to manufacture its proprietary high-purity, multi-phage cocktails for future clinical trials.
This facility is a key milestone for initiating pivotal studies, including the advancement of AP-SA02 into a potential pivotal Phase 3 trial in 2026, subject to FDA review.
The facility also supports future commercial production and potential partnering and contract manufacturing opportunities, aligning with efforts to secure the essential medicine supply chain through domestic manufacturing.

Nov 10, 2025, 12:00 PM

Press Release

Armata Pharmaceuticals Highlights Positive Phase 2a diSArm Study Results for AP-SA02

ARMP

New Projects/Investments

Armata Pharmaceuticals, Inc. (ARMP) announced positive results from its recently completed Phase 2a diSArm study of AP-SA02 for complicated Staphylococcus aureus bacteremia, presented at IDWeek 2025TM on October 22, 2025.
The study demonstrated higher Day 12 clinical response rates for the AP-SA02 group (88%) compared to the placebo group (58%).
Patients treated with AP-SA02 showed no non-response or relapse (0%) at one week post-BAT or at End of Study, in contrast to approximately 25% in the placebo group.
AP-SA02 was well-tolerated with no serious adverse events related to the study drug, and these findings strongly support advancing to a pivotal Phase 3 trial planned for 2026.

Oct 22, 2025, 3:15 PM

8-K

Armata Pharmaceuticals Highlights Positive Phase 2a diSArm Study Results for AP-SA02

ARMP

New Projects/Investments

Armata Pharmaceuticals highlighted positive results from its recently completed Phase 2a diSArm study of AP-SA02 as a potential treatment for complicated Staphylococcus aureus bacteremia (SAB) at IDWeek 2025.
The study demonstrated higher day 12 clinical response rates in the AP-SA02 group, with 88% (21/24) assessed by blinded site investigators and 83% (20/24) by the blinded Adjudication Committee, compared to 58% (7/12) in the placebo group for both assessments.
No patients in the AP-SA02 group experienced non-response or relapse (0%) at one week post-BAT or End of Study, contrasting with approximately 25% in the placebo group.
AP-SA02 was well-tolerated, with no serious adverse events related to the study drug.
The company plans to initiate a pivotal Phase 3 trial in 2026, subject to review and feedback from the U.S. Food and Drug Administration (FDA), based on these results.